| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 141, Issue 10 3263-3269, Copyright © 1988 by American Association of Immunologists
ARTICLES |
AD Hess, MK Silanskis, AH Esa, GR Pettit and WS May
Bone Marrow Transplant Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
The immunologic effects of bryostatin (Bryo), a PKC activator with antineoplastic activity, were assessed and compared to PMA. Bryo induced IL-2R expression on CD4+ and CD8+ human T lymphocytes with a dose response comparable to PMA. However, Bryo induced only a marginal proliferative response as compared with the vigorous response induced by PMA. Bryo mediated functional receptor expression because the proliferative response was enhanced by addition of rIL-2. Furthermore, the proliferative response was inhibited by the relatively specific Ca+, phospholipid-dependent protein kinase (PKC) inhibitor, H-7, indicating a role of PKC in Bryo-induced activation. Addition of the calcium ionophore, ionomycin, to Bryo-stimulated lymphocytes resulted in the production and secretion of IL-2 with a concomitant proliferative response. This effect of the calcium ionophore could be inhibited by cyclosporine with identical results obtained in PMA- stimulated cultures. A most intriguing finding was that Bryo could effectively antagonize PMA-induced T cell proliferation. Although this mechanism of inhibition is unclear, a discussion with respect to differential effects on potential intracellular PKC isoforms is provided. These studies indicated that Bryo has potent immunopotentiating properties that share some similar effects of the phorbol ester, PMA, but offers the additional property of modulating other phorbol ester effects on proliferation.
This article has been cited by other articles:
|
|
 |
|
  J. D. Roberts, M. R. Smith, E. J. Feldman, L. Cragg, M. M. Millenson, G. J. Roboz, C. Honeycutt, R. Thune, K. Padavic-Shaller, W. H. Carter, et al. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clin. Cancer Res., October 1, 2006; 12(19): 5809 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Do, V. L. Hegde, P. S. Nagarkatti, and M. Nagarkatti Bryostatin-1 Enhances the Maturation and Antigen-Presenting Ability of Murine and Human Dendritic Cells Cancer Res., September 15, 2004; 64(18): 6756 - 6765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Matsui, D. E. Gladstone, M. S. Vala, J. P. Barber, R. A. Brodsky, B. D. Smith, and R. J. Jones The Role of Growth Factors in the Activity of Pharmacological Differentiation Agents Cell Growth Differ., June 1, 2002; 13(6): 275 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy J. Immunol., November 1, 2001; 167(9): 4828 - 4837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Bosco, S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rgamma Chain Expression Blood, May 1, 1997; 89(9): 3402 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Lindern, M. P.-v. Amelsvoort, T. van Dijk, E. Deiner, E. van den Akker, S. van Emst-de Vries, P. Willems, H. Beug, and B. Lowenberg Protein Kinase C alpha Controls Erythropoietin Receptor Signaling J. Biol. Chem., October 27, 2000; 275(44): 34719 - 34727. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
